Ankylosing Spondylitis Trial, Recruiting NCT06905288 Sponsor: Novartis Pharmaceuticals Condition: Ankylosing Spondylitis
Back to Ankylosing Spondylitis

Ankylosing Spondylitis Trial, Recruiting

NCT06905288
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with ankylosing spondylitis (AS) according to a specific set of medical guidelines called the modified 1984 New York criteria
  • Your AS is currently active, meaning your symptoms are significant enough to score 4 or higher on a standard symptom questionnaire called the BASDAI
  • You have never previously taken any medications from the TNF inhibitor, JAK inhibitor, or IL-17 inhibitor drug families (common examples include adalimumab, tofacitinib, or ixekizumab — confirm with trial site)
  • You are considered suitable for treatment with a medication called secukinumab, based on official guidelines from the Ministry of Food and Drug Safety
  • You were diagnosed with AS less than 5 years ago
  • You are between 18 and 40 years old
  • You are willing and able to give written consent to take part in the study

Who may not be able to join:

  • You have a physical or mental health condition that would make it difficult to take part in the full study period (approximately 28 weeks)
  • You have spinal deformities that were present from birth or caused by an injury
  • You are currently taking part in another clinical trial
  • You have any medical reasons why taking secukinumab would not be safe for you (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +41613241111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
2 April 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Change from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov